CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
GLP-1s linked to smell and taste impairment in diabetes patients
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
Walgreens Pharmacists Help Medicare Patients Navigate New Access to GLP‑1 Medications
Bank sees structural strength in GLP-1 market as obesity drives demand
Global Partners (GLP) Surges 6.9%: Is This an Indication of Further Gains?
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Is Global Partners (GLP) Stock Undervalued Right Now?
NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets
Ozempic Linked To Lower Risk Of Violence In New Study
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion
Why People are Drinking Less & GLP-1 Drug Impact on Alcohol Consumption
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
The GLP-1 stock nobody is pricing in isn't a drugmaker
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
2 Highly Ranked Stocks to Consider After May's Hot CPI Report: DOW, GLP
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
Gen Z and GLP-1 drugs to power Gym Group's growth, says analyst
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Promino Launches Muscle Health Research Initiative Targeting GLP-1 Weight Management Market
Use of GLP-1 drugs early in pregnancy should not cause alarm
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Top Stocks With Solid Shareholder Yield Amid Rising AI Valuation Concern
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
The Wegovy pill is still dominating the GLP-1 pill market
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
New PatentVest Pulse Report Maps the Emerging Muscle-Preservation Category Expanding the GLP-1 Opportunity
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Should Value Investors Buy Global Partners (GLP) Stock?
Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients